- Home
- PBA vs WAT Comparison
PBA vs WAT Comparison
Compare PBA & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBA
- WAT
- Stock Information
- Founded
- PBA 1997
- WAT 1958
- Country
- PBA Canada
- WAT United States
- Employees
- PBA N/A
- WAT N/A
- Industry
- PBA Oil & Gas Production
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- PBA Energy
- WAT Industrials
- Exchange
- PBA Nasdaq
- WAT Nasdaq
- Market Cap
- PBA 22.6B
- WAT 17.4B
- IPO Year
- PBA N/A
- WAT 1995
- Fundamental
- Price
- PBA $37.79
- WAT $371.97
- Analyst Decision
- PBA
- WAT Buy
- Analyst Count
- PBA 0
- WAT 13
- Target Price
- PBA N/A
- WAT $379.00
- AVG Volume (30 Days)
- PBA 997.9K
- WAT 712.2K
- Earning Date
- PBA 11-06-2025
- WAT 11-04-2025
- Dividend Yield
- PBA 5.29%
- WAT N/A
- EPS Growth
- PBA N/A
- WAT 3.82
- EPS
- PBA 2.18
- WAT 10.88
- Revenue
- PBA $5,911,897,112.00
- WAT $3,105,638,000.00
- Revenue This Year
- PBA $11.25
- WAT $7.12
- Revenue Next Year
- PBA $7.55
- WAT $6.22
- P/E Ratio
- PBA $17.36
- WAT $34.20
- Revenue Growth
- PBA 20.59
- WAT 6.90
- 52 Week Low
- PBA $34.13
- WAT $275.05
- 52 Week High
- PBA $43.44
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- PBA 43.58
- WAT 72.54
- Support Level
- PBA $37.17
- WAT $340.09
- Resistance Level
- PBA $38.02
- WAT $382.02
- Average True Range (ATR)
- PBA 0.49
- WAT 11.45
- MACD
- PBA -0.06
- WAT 0.89
- Stochastic Oscillator
- PBA 41.89
- WAT 81.18
About PBA Pembina Pipeline Corp. (Canada)
Pembina Pipeline is a midstream company serving the Canadian and North American (primarily Bakken) markets with an integrated product portfolio. Its operations include transmission pipelines, oil and gas gathering, fractionation, storage, and natural gas liquid exports.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.